Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
22 10월 2024 - 9:00PM
European Patent Office to grant a patent for DRP®
companion diagnostic for Allarity’s stenoparib cancer therapy
Patent applications for the Stenoparib DRP® are
also pending in the US, Japan, China, Australia, and India
Boston (October 22, 2024) — Allarity
Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a
clinical-stage pharmaceutical company dedicated to developing
personalized cancer treatments using its proprietary, drug-specific
patient selection technology, today announced that the European
Patent Office (EPO) has issued a formal notice of its intention to
grant a patent for Allarity’s Drug Response Predictor (DRP®)
companion diagnostic specific to stenoparib, the Company’s
dual-targeted PARP/Tankyrase inhibitor.
This patent represents a significant step forward in securing
Allarity’s market position for stenoparib and the Stenoparib DRP
companion diagnostic, which identifies patients most likely to
derive clinical benefit from stenoparib treatment. Thomas Jensen,
CEO of Allarity Therapeutics, commented, “As we advance our
clinical program for stenoparib, we are also focused on securing
patents in key markets to pave the way for potential future
commercialization. Though our main focus is to first achieve
regulatory approval in the US for both stenoparib and its DRP
companion diagnostic, we strongly believe stenoparib has the
potential to help ovarian cancer patients worldwide. Therefore,
knowing that the EPO intends to grant us a European patent for the
Stenoparib DRP is an important step towards securing the foundation
for an international market position for stenoparib and its
companion diagnostic."Patent applications for the Stenoparib DRP
companion diagnostic are also pending in the United States, Japan,
China, Australia, and India. Allarity has previously been granted
17 patents for drug-specific DRPs, including eight in the United
States.
About StenoparibStenoparib is an orally
available, small-molecule, dual-targeted inhibitor of PARP1/2 and
Tankyrase 1 and 2. At present, tankyrases are attracting
significant attention as emerging therapeutic targets for cancer,
principally due to their role in regulating the Wnt signaling
pathway. Aberrant Wnt/β-catenin signaling has been implicated in
the development and progression of numerous cancers. By inhibiting
PARP and also blocking Wnt pathway activation, stenoparib’s unique
therapeutic action shows potential as a promising therapeutic.
Allarity has exclusive global rights for the development and
commercialization of stenoparib, which was originally developed by
Eisai Co. Ltd. and was formerly known under the names E7449 and
2X-121.
About the Drug Response Predictor – DRP® Companion
DiagnosticAllarity uses its drug-specific DRP® to select
those patients who, by the gene expression signature of their
cancer, are found to have a high likelihood of benefiting from a
specific drug. By screening patients before treatment, and only
treating those patients with a sufficiently high, drug-specific DRP
score, the therapeutic benefit rate may be significantly increased.
The DRP method builds on the comparison of sensitive vs. resistant
human cancer cell lines, including transcriptomic information from
cell lines combined with clinical tumor biology filters and prior
clinical trial outcomes. DRP is based on messenger RNA expression
profiles from patient biopsies. The DRP® platform has proven its
ability to provide a statistically significant prediction of the
clinical outcome from drug treatment in cancer patients dozens of
clinical studies (both retrospective and prospective). The DRP
platform, which can be used in all cancer types and is patented for
more than 70 anti-cancer drugs, has been extensively published in
the peer-reviewed literature.
About Allarity TherapeuticsAllarity
Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage
biopharmaceutical company dedicated to developing personalized
cancer treatments. The Company is focused on development of
stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian
cancer patients, using its DRP® companion diagnostic for patient
selection in the ongoing phase 2 clinical trial, NCT03878849.
Allarity is headquartered in the U.S., with a research facility in
Denmark, and is committed to addressing significant unmet medical
needs in cancer treatment. For more information, visit
www.allarity.com.
Follow Allarity on Social MediaLinkedIn:
https://www.linkedin.com/company/allaritytx/X:
https://twitter.com/allaritytx
Forward-Looking Statements This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements provide the Company’s current expectations or forecasts
of future events. The words “anticipates,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predicts,” “project,” “should,” “would”
and similar expressions may identify forward-looking statements,
but the absence of these words does not mean that a statement is
not forward-looking. These forward-looking statements include, but
are not limited to, statements regarding the anticipated clinical
advancement of stenoparib in treating advanced ovarian cancer, its
potential to deliver meaningful clinical outcomes for patients, and
the Company’s strategy to seek regulatory approval based on the
results from ongoing clinical trials. Any forward-looking
statements in this press release are based on management’s current
expectations of future events and are subject to multiple risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, potential challenges in securing sufficient
capital for continued clinical operations, uncertainties regarding
the interpretation of clinical trial results, the risk that
positive initial data may not be confirmed in larger studies,
delays or failures in obtaining necessary regulatory approvals, and
challenges in bringing stenoparib or other candidates to the
market. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in our Form S-1
registration statement filed on October 30, 2023, as amended and
our Form 10-K annual report on file with the Securities and
Exchange Commission (the “SEC”), available at the SEC’s website at
www.sec.gov, and as well as discussions of potential risks,
uncertainties and other important factors in the Company’s
subsequent filings with the SEC. All information in this press
release is as of the date of the release, and the Company
undertakes no duty to update this information unless required by
law.
###
Company Contact:
investorrelations@allarity.com
Media
Contact: Thomas
Pedersen Carrotize
PR &
Communications +45
6062 9390 tsp@carrotize.com
- Allarity Therapeutics - Press Release Stenoparib DRP EU
Patent
Allarity Therapeutics (NASDAQ:ALLR)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Allarity Therapeutics (NASDAQ:ALLR)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
